Portfolio News

 

   
March 2013
Neurotech - Investment
SV Life Sciences Fund III invested in Neurotech, developer of an encapsulated cell therapy for the delivery of therapeutic proteins in retinal diseases, as part of a $3m bridge loan financing round.  ...

Read more

Team - David Guyer, Michael Ross
August 2012
Neurotech Investment
SV Life Sciences Fund III invested in Neurotech, developer of an encapsulated cell therapy for the delivery of therapeutic proteins in retinal diseases as part of a $10m bridge loan financing round.  ...

Read more

Team - David Guyer
June 2012
EBR Systems - Investment
SV Life Sciences Fund III invested in EBR Systems, developing a wireless cardiac stimulation device (WiCS) to compete in the cardiac resynchronization therapy space for treatment of congestive heart failure as part of a $8m bridge loan financing round.  ...

Read more

Team - James Garvey, David Milne
May 2012
Patient Care Exit
SV Life Sciences notes that in May 2010 – Almost Family (Nasdaq: AFAM) entered into a definitive agreement to acquire all stock of Patient Care. The total purchase price for the stock is $45.2m, subject to a working capital adjustment ...

Read more

Team - Eugene Hill
May 2012
Neurotech Investment
SV Life Sciences Fund III invested in Neurotech, developer of an encapsulated cell therapy for the delivery of therapeutic proteins in retinal diseases as part of a $2m bridge loan financing round. ...

Read more

Team - David Guyer
October 2011
Concentric Medical Exit
SV Life Sciences notes that in October 2011 – Stryker (NYSE:SYK) entered into a definitive agreement to acquire Concentric Medical for £135m in an all-cash transaction.  ...

Read more

Team - James Garvey, Greg Madden
July 2011
CoreLab (Medifacts) - Investment
SV Life Sciences Fund III invested in CoreLab, provides ECG core lab services related to cardiac safety testing for global clinical trials as part of a $7m series C financing round. ...

Read more

Team - Eugene Hill
June 2011
Lux Biosciences - Investment
SV Life Sciences Fund III invested in Lux Biosciences, developing drugs for ophthalmic diseases. Their lead product is LX211, an oral drug for the treatment of uveitis as part of a $6m bridge loan financing round. ...

Read more

Team - David Guyer
March 2011
Lux Biosciences - Investment
SV Life Sciences Fund III invested in Lux Biosciences, developing drugs for ophthalmic diseases. Their lead product is LX211, an oral drug for the treatment of uveitis as part of a $1.5m bridge loan financing round. ...

Read more

Team - David Guyer
March 2011
Lux Biosciences - Investment
SV Life Sciences Fund III invested in Lux Biosciences, developing drugs for ophthalmic diseases. Their lead product is LX211, an oral drug for the treatment of uveitis as part of a $5.4m bridge loan financing round. ...

Read more

Team - David Guyer
February 2011
Socios Mayores Exit
SV Life Sciences notes that in February 2011 – Triple-S Management Corporation (NYSE:GTS) entered into a definitive agreement to acquire all of the outstanding stock of Socio Mayores en Salud Holdings (SMSH) – the parent company of American Health for $82 million in a transaction funded with unrestricted cash.  ...

Read more

Team - Eugene Hill
January 2011
Sadra Medical Exit
SV Life Sciences notes that in January 2011 – Boston Scientific Corporation (NYSE: BSX) entered into a definitive agreement to purchase Sadra Medical for a total price of $193m, 86 percent of Sadra Medical’s equity not already owned by Boston Scientific. Additional payments of up to $193m are contingent upon achievement of specified regulatory and revenue-based criteria through 2016.

Read more

Team - James Garvey, David Milne
January 2011
EBR Systems - Investment
SV Life Sciences Fund III invested in EBR Systems, developing a wireless cardiac stimulation device (WiCS) to compete in the cardiac resynchronization therapy space for treatment of congestive heart failure as part of a $10m series D financing round.  ...

Read more

Team - David Milne
January 2011
CHF Solutions Exit
SV Life Sciences notes that in January 2011 – Gambro entered into a definitive agreement to purchase CHF Solutions, a medical device company that manufactures and distributes devices to treat fluid overload. Financial terms of the deal were not disclosed. DENVER, Jan. 20 /PRNewswire/ -- Gambro and CHF Solutions, Inc. (CHF) announced today that Gambro has acquired CHF, a medical device company that manufactures and distributes ultrafiltration devices to treat fluid overload.

Read more

Team - James Garvey

⇧ Back to top